A Case of Ceftriaxone-associated Biliary Pseudolithiasis in an Elderly Patient with Renal Dysfunction

Overview

Journal IDCases

Specialty Infectious Diseases

Date 2017 Jul 15

PMID 28706853

Citations 6

Authors

Shuichi Abe

Affiliations

Soon will be listed here.

Abstract

Prior literature suggests that ceftriaxone causes formation of gallbladder stones at a relatively high frequency, and when abdominal symptoms occur, prompt investigation of the gallbladder is required with institution of appropriate treatment. Aging, malnutrition, renal impairment, and sepsis are risk factors for pseudolithiasis, and prevention of these is important to suppress gallstone development.

Citing Articles

Factors influencing the cure of pseudolithiasis: a retrospective study of 264 patients.

Deng L, Deng J BMC Gastroenterol. 2025; 25(1):105.

PMID: 39987035 PMC: 11847377. DOI: 10.1186/s12876-025-03704-6.

The Assessment and Efficiency of Cefixime in Upper Respiratory Tract Infections: Insights and Perspectives.

Shafi M, Shah A, Khan M, Faisal S, Iqbal S Cureus. 2024; 16(7):e64539.

PMID: 39144897 PMC: 11322408. DOI: 10.7759/cureus.64539.

Ceftriaxone-associated Biliary Pseudolithiasis with Elderly Type 1 Diabetes Mellitus: Two Case Reports.

Kanazawa K, Suzuki S, Inaba T, Koga S, Kuwabara K Intern Med. 2023; 62(22):3367-3371.

PMID: 37032086 PMC: 10713371. DOI: 10.2169/internalmedicine.1405-22.

Rapid Onset of Ceftriaxone-Induced Cholelithiasis in an Adult Patient.

Abdelaziz H, Cormier N, Levesque T, St-Yves J, Habash M, Diaz O J Glob Infect Dis. 2022; 14(1):31-34.

PMID: 35418730 PMC: 8996453. DOI: 10.4103/jgid.jgid_11_21.

Ceftriaxone-Induced Pancreatitis.

Albugami M, Ahmed M, Shihah A Can J Hosp Pharm. 2021; 74(3):291-293.

PMID: 34248170 PMC: 8237964. DOI: 10.4212/cjhp.v74i3.3157.

References

Schaad U, Tschaeppeler H . Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet. 1988; 2(8625):1411-3. DOI: 10.1016/s0140-6736(88)90596-x. View

Papadopoulou F, Efremidis S, Karyda S, Badouraki M, Karatza E, Panteliadis C . Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr. 2000; 88(12):1352-5. DOI: 10.1080/080352599750030077. View

Richards D, Heel R, Brogden R, Speight T, Avery G . Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984; 27(6):469-527. DOI: 10.2165/00003495-198427060-00001. View

Shiffman M, Keith F, Moore E . Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. 1990; 99(6):1772-8. DOI: 10.1016/0016-5085(90)90486-k. View

Riccabona M, Kerbl R, Schwinger W, Spork D, Millner M, Grubbauer H . [Ceftriaxone-induced cholelithiasis--a harmless side-effect?]. Klin Padiatr. 1993; 205(6):421-3. DOI: 10.1055/s-2007-1025261. View

Brogard J, Blickle J, Jehl F, Arnaud J, Paris-Bockel D, Monteil H . High biliary elimination of ceftriaxone in man. Int J Clin Pharmacol Ther Toxicol. 1988; 26(4):167-72. View

Araz N, Okan V, Demirci M, Araz M . Pseudolithiasis due to ceftriaxone treatment for meningitis in children: report of 8 cases. Tohoku J Exp Med. 2007; 211(3):285-90. DOI: 10.1620/tjem.211.285. View

Cohen D, Appel G, Scully B, Neu H . Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis. Antimicrob Agents Chemother. 1983; 24(4):529-32. PMC: 185368. DOI: 10.1128/AAC.24.4.529. View

Biner B, Oner N, Celtik C, Bostancioglu M, Tuncbilek N, Guzel A . Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2006; 34(5):217-22. DOI: 10.1002/jcu.20228. View

10.

McNamara P, Stoeckel K, ZIEGLER W . Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur J Clin Pharmacol. 1982; 22(1):71-5. DOI: 10.1007/BF00606428. View

11.

Palanduz A, Yalcin I, Tonguc E, Guler N, Ones U, Salman N . Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2001; 28(4):166-8. DOI: 10.1002/(sici)1097-0096(200005)28:4<166::aid-jcu2>3.0.co;2-g. View

12.

Robertson F, Crombleholme T, Barlow S, Verhave M, Brown D . Ceftriaxone choledocholithiasis. Pediatrics. 1996; 98(1):133-5. View

13.

Murata S, Aomatsu T, Yoden A, Tamai H . Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis. Pediatr Int. 2015; 57(5):942-6. DOI: 10.1111/ped.12625. View